The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea

Helicobacter

Volumn 13, Issue 2, 2008, Pages 146-156

  Kang, Jung Mook ^a   Kim, Nayoung ^a,b   Yoo, Ji Youn ^b   Park, Young Soo ^a,b   Lee, Dong Ho ^a,b   Kim, Hyun Young ^b   Lee, Hye Seung ^b   Choe, Gheeyoung ^b   Kim, Joo Sung ^a   Jung, Hyun Chae ^a   Song, In Sung ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Atrophic gastritis; Dysplasia; Gastric cancer; Helicobacter pylori; Pepsinogen

Indexed keywords

GASTRIN; PEPSINOGEN I; PEPSINOGEN II;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; CANCER DIAGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CHRONIC INFLAMMATION; DISEASE ACTIVITY; DISEASE SEVERITY; ERADICATION THERAPY; FEMALE; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; KOREA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH CANCER; STOMACH DISEASE;

ANTIGENS, BACTERIAL; BIOLOGICAL MARKERS; GASTRINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KOREA; PEPSINOGENS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS;

HELICOBACTER PYLORI;

EID: 40449127747     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2008.00592.x     Document Type: Article

References (69)

1. Miki K, Ichinose M, Kawamura N, et al. The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. Jpn J Cancer Res 1989 80: 111 4.
2. Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology 1982 83: 204 9.
3. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995 19: S37 43.
4. Borch K, Axelsson CK, Halgreen H, et al. The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. Scand J Gastroenterol 1989 24: 870 6.
5. Yamada S, Matsuhisa T, Makonkawkeyoon L, et al. Helicobacter pylori infection in combination with the serum pepsinogen I/II ratio and interleukin-1beta-511 polymorphisms are independent risk factors for gastric cancer in Thais. J Gastroenterol 2006 41: 1169 77.
6. Kitahara F, Shimazaki R, Sato T, et al. Severe atrophic gastritis with Helicobacter pylori infection and gastric cancer. Gastric Cancer 1998 1: 118 24.
7. Korstanje A, den Hartog G, Biemond I, Lamers CB. The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature. Scand J Gastroenterol Suppl 2002, 22 6.
8. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006 9: 245 53.
9. Kitahara F, Kobayashi K, Sato T, et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999 44: 693 7.
10. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007 12: 333 40.
11. Dinis-Ribeiro M, Yamaki G, Miki K, et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004 11: 141 7.
12. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis 2007 8: 8 14.
13. Mukoubayashi C, Yanaoka K, Ohata H, et al. Serum pepsinogen and gastric cancer screening. Intern Med 2007 46: 261 6.
14. Vaananen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003 15: 885 91.
15. Oksanen A, Sipponen P, Miettinen A, Sarna S, Rautelin H. Evaluation of blood tests to predict normal gastric mucosa. Scand J Gastroenterol 2000 35: 791 5.
16. Schlemper RJ, van der Werf SD, Biemond I, Lamers CB. Seroepidemiology of gastritis in Japanese and Dutch male employees with and without ulcer disease. Eur J Gastroenterol Hepatol 1996 8: 33 9.
17. Sipponen P, Ranta P, Helske T, et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol 2002 37: 785 91.
18. Westerveld BD, Pals G, Lamers CB, et al. Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer 1987 59: 952 8.
19. Mulholland G, Ardill JE, Fillmore D, et al. Helicobacter pylori related hypergastrinaemia is the result of a selective increase in gastrin 17. Gut 1993 34: 757 61.
20. Calam J, Gibbons A, Healey ZV, Bliss P, Arebi N. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 1997 113: S43 9 Discussion S50.
21. Ferrand A, Wang TC. Gastrin and cancer: a review. Cancer Lett 2006 238: 15 29.
22. Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori. Gut 1993 34: 888 92.
23. el-Omar EM, Penman ID, Ardill JE, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995 109: 681 91.
24. Loffeld RJ, Stobberingh E, Flendrig JA, Arends JW. Helicobacter pylori in gastric biopsy specimens. Comparison of culture, modified Giemsa stain, and immunohistochemistry. A retrospective study. J Pathol 1991 165: 69 73.
25. Kim N, Kim JM, Kim CH, et al. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol 2006 40: 683 7.
26. Genta RM, Robason GO, Graham DY. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol 1994 25: 221 6.
27. Yoo JY, Kim N, Park YS, et al. Detection rate of Helicobacter pylori against a background of atrophic gastritis and/or intestinal metaplasia. J Clin Gastroenterol 2007 41: 751 5.
28. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996 20: 1161 81.
29. Kim SY, Ahn JS, Ha YJ, et al. Serodiagnosis of Helicobacter pylori infection in Korean patients using enzyme-linked immunosorbent assay. J Immunoassay 1998 19: 251 70.
30. Kim JH, Kim HY, Kim NY, et al. Seroepidemiological study of Helicobacter pylori infection in asymptomatic people in South Korea. J Gastroenterol Hepatol 2001 16: 969 75.
31. Khulusi S, Mendall MA, Patel P, et al. Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects. Gut 1995 37: 319 24.
32. Di Mario F, Cavallaro LG, Moussa AM, et al. Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium. Dig Dis Sci 2006 51: 1791 5.
33. Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992 102: 760 6.
34. Biasco G, Paganelli GM, Vaira D, et al. Serum pepsinogen I and II concentrations and IgG antibody to Helicobacter pylori in dyspeptic patients. J Clin Pathol 1993 46: 826 8.
35. Wagner S, Haruma K, Gladziwa U, et al. Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication. Am J Gastroenterol 1994 89: 1211 8.
36. Ricci C, Vakil N, Rugge M, et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol 2004 99: 1910 5.
37. Ohkusa T, Miwa H, Nomura T, et al. Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: comparison with H. pylori-negative patients. Aliment Pharmacol Ther 2004 20: 25 32.
38. Urita Y, Hike K, Torii N, et al. Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig Dis Sci 2004 49: 795 801.
39. Stemmermann GN, Nomura AM. The relation of pepsinogen group II (PGII) expression to intestinal metaplasia and gastric cancer. Histopathology 2006 49: 45 51.
40. Broutet N, Plebani M, Sakarovitch C, Sipponen P, Megraud F. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer 2003 88: 1239 47.
41. Kodoi A, Yoshihara M, Sumii K, Haruma K, Kajiyama G. Serum pepsinogen in screening for gastric cancer. J Gastroenterol 1995 30: 452 60.
42. Yoshihara M, Sumii K, Haruma K, et al. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol 1998 93: 1090 6.
43. Hattori Y, Tashiro H, Kawamoto T, Kodama Y. Sensitivity and specificity of mass screening for gastric cancer using the measurement of serum pepsinogens. Jpn J Cancer Res 1995 86: 1210 5.
44. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992 52: 6735 40.
45. Nardone G. Review article: molecular basis of gastric carcinogenesis. Aliment Pharmacol Ther 2003 17: 75 81.
46. Oishi Y, Kiyohara Y, Kubo M, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006 163: 629 37.
47. Fujishiro M, Oka M, Yahagi N, et al. Correlation of serum pepsinogens and gross appearances combined with histology in early gastric cancer. J Exp Clin Cancer Res 2006 25: 207 12.
48. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004 109: 138 43.
49. Hansen S, Vollset SE, Derakhshan MH, et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007 56: 918 25.
50. Kokkola A, Louhimo J, Puolakkainen P, et al. Helicobacter pylori infection and low serum pepsinogen I level as risk factors for gastric carcinoma. World J Gastroenterol 2005 11: 1032 6.
51. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005 54: 764 8.
52. Chuang CH, Sheu BS, Yang HB, et al. Hypergastrinemia after Helicobacter pylori infection is associated with bacterial load and related inflammation of the oxyntic corpus mucosa. J Gastroenterol Hepatol 2004 19: 988 93.
53. Cao Q, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis 2007 8: 15 22.
54. Chen TS, Tsay SH, Chang FY, Lee SD. Effect of eradication of Helicobacter pylori on serum pepsinogen I, gastrin, and insulin in duodenal ulcer patients: a 12-month follow-up study. Am J Gastroenterol 1994 89: 1511 4.
55. Bodger K, Wyatt JI, Heatley RV. Variation in serum pepsinogens with severity and topography of Helicobacter pylori-associated chronic gastritis in dyspeptic patients referred for endoscopy. Helicobacter 2001 6: 216 24.
56. Iijima K, Ohara S, Sekine H, et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut 2000 46: 20 6.
57. Kawai T, Miki K, Ichinose M, et al. Changes in evaluation of the pepsinogen test result following Helicobacter pylori eradication therapy in Japan. Inflammopharmacology 2007 15: 31 5.
58. Al-Assi MT, Miki K, Walsh JH, et al. Noninvasive evaluation of Helicobacter pylori therapy: role of fasting or postprandial gastrin, pepsinogen I, pepsinogen II, or serum IgG antibodies. Am J Gastroenterol 1999 94: 2367 72.
59. Perez-Paramo M, Albillos A, Calleja JL, et al. Changes in gastrin and serum pepsinogens in monitoring of Helicobacter pylori response to therapy. Dig Dis Sci 1997 42: 1734 40.
60. Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001 134: 380 6.
61. Satoh K, Kimura K, Takimoto T, Kihira K. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter 1998 3: 236 40.
62. Ito M, Haruma K, Kamada T, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002 16: 1449 56.
63. Annibale B, Di Giulio E, Caruana P, et al. The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis. Aliment Pharmacol Ther 2002 16: 1723 31.
64. Lu B, Chen MT, Fan YH, Liu Y, Meng LN. Effects of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study. World J Gastroenterol 2005 11: 6518 20.
65. Yamaji Y, Mitsushima T, Ikuma H, et al. Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects. Gut 2001 49: 335 40.
66. Kang HY, Kim N, Park YS, et al. Progression of atrophic gastritis and intestinal metaplasia drives Helicobacter pylori out of the gastric mucosa. Dig Dis Sci 2006 51: 2310 5.
67. Testoni PA, Bonassi U, Bagnolo F, Colombo E, Scelsi R. In diffuse atrophic gastritis, routine histology underestimates Helicobacter pylori infection. J Clin Gastroenterol 2002 35: 234 9.
68. Karnes WE Jr., Samloff IM, Siurala M, et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology 1991 101: 167 74.
69. Kokkola A, Kosunen TU, Puolakkainen P, et al. Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. APMIS 2003 111: 619 24.